This article is more than 5 years old. Information may no longer be current.
Fluocinolone acetonide implant improves control of inflammation in uveitis
Click Here to Manage Email Alerts
LAS VEGAS — An intravitreal fluocinolone acetonide implant appears to delay and reduce the recurrence of uveitis-related inflammation while stabilizing visual acuity, according to a surgeon speaking here.
Carlos E. Pavesio, MD, an colleagues evaluated the efficacy of the implant in 66 patients and compared them to 74 control patients who received standard of care. Dr. Pavesio discussed the 2-year results of the study at the American Academy of Ophthalmology meeting.
So far, the study has found no significant differences in visual acuity between control patients and those who received the implant. However, patients who received the implant had a 35% rate of recurrence of uveitis compared to a 64.9% recurrence rate among control patients, he said.
Dr. Pavesio acknowledged that adverse events such as cataracts and increased IOP were common among patients who receive the implants. He cautioned users to pay attention to the implant wounds.
The study, in which 37 centers are participating, is ongoing. Patients will be followed for another year, he said.